Search for: "Martin Price" Results 581 - 600 of 1,881
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Sep 2017, 1:43 am by Joseph Leahy
Yesterday, the New York Times trumpeted a new internet company, Loftium, and its interesting, new-economy business model (which, for the time being, operates only in Seattle): Loftium will provide prospective homebuyers with up to $50,000 for a down payment, as long as they are willing to continuously list an extra bedroom on Airbnb for one to three years and share most of the income with Loftium over that time. [read post]
19 Sep 2017, 3:55 pm by Kevin LaCroix
Lockheed Martin Corp., settled for $62 million, earning the firm an eye-opening $22.3 million in fees and expenses. [read post]
17 Sep 2017, 3:48 pm by Sabrina I. Pacifici
The right to loan articles is “deeply engraved” into German law, he explained, and publishers have to allow it unless libraries can pay per article at a reasonable price…” [read post]
14 Sep 2017, 11:15 pm by Tessa Shepperson
Rent Controls and variable house prices There are the usual plethora of posts on rents and prices. [read post]
NEW YORK –  In the two years since bursting onto the national scene, Martin Shkreli has often appeared to be his own worst enemy. [read post]
13 Sep 2017, 5:00 pm
So what was United States District Court Judge Kiyo Matsumoto thinking this week when he revoked bail for Martin Shkreli? [read post]
8 Sep 2017, 11:48 am by Geoffrey B. Fehling
The platform’s capabilities include: “the ability to create and maintain asset data from multiple parties; to link data to policy contracts; to receive and act upon information that results in a pricing or a business process change; to connect client assets, transactions and payments; and to capture and validate up-to-date first notification or loss data. [read post]
8 Sep 2017, 6:00 am
Political Uncertainty and Firm Disclosure Posted by Audra Boone, Texas Christian University, on Friday, September 1, 2017 Tags: Capital markets, Disclosure, Filings, Form 8-K, Information asymmetries, Information environment, Management, Market conditions, Market reaction, SEC, Transparency, Voluntary Disclosure Corporate Governance—the New Paradigm Posted by Martin Lipton, Wachtell, Lipton, Rosen & Katz,… [read post]
7 Sep 2017, 8:04 am by Kelly Phillips Erb
Gains and losses are figured by calculating the difference in sales prices less basis (generally, purchase price plus any adjustments). [read post]
6 Sep 2017, 9:41 am by Mark Astarita
  According to the SEC’s complaint, investors were falsely promised high returns from the price markups in ticket resales. [read post]
1 Sep 2017, 9:02 am by admin
Peter Martin has a 50-year record of public service. [read post]
25 Aug 2017, 3:00 am by Christopher Tyner
  Harper’s Magazine has published highly entertaining excerpts from the jury selection process in the recent securities and wire fraud trial of Martin Shkreli, the former CEO of Turing Pharmaceuticals who raised the price of a drug commonly used to treat certain life-threatening infections by five-thousand percent overnight. [read post]
14 Aug 2017, 10:53 am by Altman & Altman
Earlier this month Martin Shkreli, the man who became infamous for jacking up the price of an AIDS medication, was convicted of securities fraud for the mismanagement of investment funds. [read post]
11 Aug 2017, 5:00 am by eileen peck
Shkreli achieved notoriety for raising the per-dose price of an AIDS drug from $13 to $750. [read post]
8 Aug 2017, 2:10 pm by Paul Rugani
After a five-week trial, a jury of five men and seven women convicted notorious pharmaceutical executive Martin Shkreli of securities fraud on August 4, 2017. [read post]
8 Aug 2017, 2:10 pm by Paul Rugani
After a five-week trial, a jury of five men and seven women convicted notorious pharmaceutical executive Martin Shkreli of securities fraud on August 4, 2017. [read post]
4 Aug 2017, 1:27 pm by Bloomberg
Martin Shkreli, once dubbed “the most hated man in America,” is now a convicted felon. [read post]
4 Aug 2017, 11:54 am by Beth Mole
Enlarge / NEW YORK, NY - AUGUST 4: Former pharmaceutical executive Martin Shkreli arrives at the U.S. [read post]
31 Jul 2017, 8:22 am by Beth Mole
(credit: Getty | Drew Angerer) The fate of Martin Shkreli is now with the jury. [read post]